October 2012

About Authors:
Gunjan Kalyani^*, Vishal S. Deshmukh, Pranita Kashyap, Yogesh Vaishnav, Ajit Kumar Pandey
Shri Rawatpura Sarkar Institute of Pharmacy,
Kumhari, Durg, Chhattisgarh.
kalyani.gunjan@yahoo.in, rvg_54767@yahoo.co.in*

Abstract:
The IUPAC Name of Salmeterol is (RS)-2-(hydroxymethyl)-4-{1-hydroxy-2-[6-(4-phenylbutoxy) hexylamino]ethyl}phenol. Salmeterol is a prescription drug that is used for treating airway spasms in people with asthma or chronic obstructive pulmonary disease (COPD). By relaxing the muscles around the airways to allow more air into and out of the lungs, the medication can help prevent asthma attacks from occurring.Salmeterol comes in the form of an inhalation powder and is generally used twice a day. Present research work deals with UV spectrophotometric method for the estimation of salmeterol in pure form. For the estimation of salmeterol, solvent system employed was ethanol and wavelength of detection (λ_det) was 252 nm. The linearity was obtained in the range 6 – 14 µg/ml, with a regression coefficient, R²= 0.999. The LOD & LOQ were found to be 4.99 µg/ml and 14.24 µg/ml respectively. Obtained results showed that there is minimum intra day and inter day variation. The developed method was validated and recovery studies were also carried out. Sample recovery using the above method was in good agreement with their respective labeled claims, thus suggesting the validity of the method and non-interference of formulation excipients in the estimation.

About Author:
Mahek Goel
Shri Baba Mastnath Institute of Pharmaceutical Science & Research
Asthal Bohar, Rohtak, Haryana (124001)
mahekgoel10@gmail.com

ABSTRACT
Parenteral drug delivery systems are the preparations that are given other than oral route. (Para-outside, enteric–intestine). Parenteral drug delivery systems are most preferred drug delivery systems as they meet many benefits over other dosage forms in many cases such as unconsciousness, nausea, in emergency clinical episodes. The Parenteral administration route is the most common and efficient for delivery of active drug substances with poor bio-availability and the drugs with a narrow therapeutic index. But parenteral route offers rapid onset of action with rapid declines of systemic drug level. For the sake of effective treatment it is often desirable to maintain systemic drug levels within the therapeutically effective concentration range for as long as treatment calls for. It requires frequent injection, which ultimately leads to patient discomfort. For this reason, drug delivery system which can reduce total number of injection throughout the effective treatment, improve patient compliance as well as pharmacoeconomic. These biodegradable injectable drug delivery system offer attractive opportunities for protein delivery and could possibly extend patent life of protein drugs.Parenteral drug delivery system seeks to optimize therapeutic index by providing immediate drug to the systemic pool in required quantity to treat– cardiac attacks, respiratory attacks. This article explores various prolonged release parenteral drug delivery system and their strategies of preparation, their potential benefits/drawbacks and in-vitro testing methods.

They are a premier research institute with all the necessary facilities that a research scientist may need. Research interests of their faculty lie in the frontier areas of biology. The talent and drive of their students and faculty continues to show us the way to good science.

About Authors:
Mr. Satyanand Tyagi
President, Tyagi Pharmacy Association & Scientific Writer,
Chattarpur, New Delhi, India.
Prof. Satyanand Tyagi is a life time member of various pharmacy professional bodies like IPA, APTI and IPGA. He has published various research papers and review articles. His academic works include 50 Publications (42 Review Articles and 08 Research Articles of Pharmaceutical, Medicinal and Clinical Importance, published in standard and reputed National and International Pharmacy journals; Out of 50 publications, 11 are International Publications).
sntyagi9@yahoo.com, +91-9871111375 / 9582025220

ABSTRACT:
Diabetic nephropathy is one of the most serious complications related to diabetes, often leading to end-stage kidney disease. Purple corn grown in Peru and Chile is a relative of blue corn, which is readily available in the U.S. The maize is rich in anthocyanins (also known as flavonoids), which are reported to have anti-diabetic properties. Scientists from the Department of Food and Nutrition and Department of Biochemistry at Hallym University in Korea investigated the cellular and molecular activity of purple corn anthocyanins (PCA) to determine whether and how it affects the development of diabetic nephropathy (DN). Their findings suggest that PCA inhibits multiple pathways involved in the development of DN, which may help in developing therapies aimed at type 2 diabetes and kidney disease. The aim of present article is to provide in depth knowledge about Purple Corn, their clinical and biological utility as well as their role in treatments of type 2 diabetes and kidney disease. An attempt is also made to focus on compounds found in purple corn which may aid in developing future treatments for type 2 Diabetes as well as kidney disease.